Oprelvekin: A review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia

BioDrugs

Volumn 10, Issue 2, 1998, Pages 159-171

  Wilde, Michelle I ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 11; PLACEBO; RECOMBINANT INTERLEUKIN 11; THIOTEPA;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DYSPNEA; EDEMA; FLUID RETENTION; HEART ATRIUM ARRHYTHMIA; HUMAN; MEGAKARYOPOIESIS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0031714801     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199810020-00006     Document Type: Review

References (38)

1. Turner KJ, Neben S, Weich N, et al. The role of recombinant interleukin 11 in megakaryocytopoiesis. Stem Cells 1996; 14 Suppl. 1: 53-61
2. Du XX, Williams DA. Interleukin-11: a multifunctional growth factor derived from the hematopoietic microenvironment. Blood 1994 Apr 15; 83: 2023-30
3. Quesniaux VFJ. Interleukin 11. Leuk Lymphoma 1994 Jul; 14: 241-9
4. Nandurkar HH, Hilton DJ, Nathan P, et al. The human IL-11 receptor requires gp130 for signalling: demonstration by molecular cloning of the receptor. Oncogene 1996 Feb 1; 12: 585-93
5. Paul SR, Bennett F, Calvetti JA, et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci U S A 1990; 87: 7512-6
6. Kobayashi S, Teramura M, Oshimi K, et al. Interleukin-11. Leuk Lymphoma 1994 Sep; 15: 45-9
7. Du X, Williams DA. Interleukin-11: review of molecular, cell biology, and clinical use. Blood 1997 Jun 1; 89: 3897-908
8. Dorner AJ, Goldman SJ, Keith Jr JC. Interleukin-11: biological activity and clinical studies. Biodrugs 1997 Dec; 8: 418-29
9. Kawashima I, Ohsumi J, Mita-Honjo K, et al. Molecular cloning of cDNA encoding adipogenesis inhibitory factor and identity with interleukin-11. FEBS Lett 1991; 283: 199
10. Du XX, Doerschuk CM, Orazi A, et al. A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 1994 Jan 1; 83: 33-7
11. Goldman SJ. Preclinical biology of interleukin 11: a multifunctional hematopoietic cytokine with potent thrombopoietic activity. Stem Cells 1995 Sep; 13: 462-71
12. Genetics Institute Inc. Neumega (oprelvekin) prescribing information. Massuchussetts, USA
13. Teramura M, Kobayashi S, Hoshino S, et al. Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 1992 Jan 15; 79: 327-31
14. Bruno E, Briddell RA, Cooper RJ, et al. Effects of recombinant interleukin-11 on human megakaryocyte progenitor cells. Exp Hematol 1991 Jun; 19: 378-81
15. Burstein SA, Mei RL, Henthorn J, et al. Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro. J Cell Physiol 1992 Nov; 153: 305-12
16. Larson D, Leary A, Hahn-Cordes L, et al. Interleukin-11 (IL-11) synergized with IL-3 in promoting human and murine megakaryocyte colony formation in vitro. Blood 1990; 76 Suppl. 1: 464a
17. Du XX, Scott D, Yang ZX, et al. Interleukin-11 stimulates multilineage progenitors, but not stem cells, in murine and human long-term marrow cultures. Blood 1995 Jul 1; 86: 128-34
18. Schlerman FJ, Bree AG, Kaviani MD, et al. Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates. Stem Cells 1996 Sep; 14: 517-32
19. Bree A, Schlerman F, Timony G, et al. Pharmacokinetics and thrombopoietic effects of recombinant human interleukin 11 (rHuIL-11) in nonhuman primates and rodents. Blood 1991; 78 Suppl.: 132a
20. Mason L, Timothy G, Perkin D, et al. Human recombinant interleukin-11 promotes maturation of bone marrow megakaryocytes in non-human primates: an electron microscopic study. Blood 1993; 82 Suppl. 1: 69a
21. Keller DC, Du XX, Srour EF, et al. Interleukin-11 inhibits adipogenesis and stimulates myelopoiesis in human long-term marrow cultures. Blood 1993 Sep 1; 82: 1428-35
22. Schibler KR, Yang YC, Christensen RD. Effect of interleukin 11 on cycling status and clonogenic maturation of fetal and adult hematopoietic progenitors. Blood 1992 Aug 15; 80: 900-3
23. Yin TG, Schendel P, Yang YC. Enhancement of in vitro and in vivo antigen-specific antibody responses by interleukin 11. J Exp Med 1992 Jan 1; 175: 211-6
24. Anderson KC, Morimoto C, Paul SR, et al. Interleukin-11 promotes accessory cell-dependent B-cell differentiation in humans. Blood 1992 Dec 1; 80: 2797-804
25. Takagi A, Masuda H, Takakura Y, et al. Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice. J Pharmacol Exp Ther 1995 Nov; 275: 537-43
26. Aoyama K, Uchida T, Takanuki F, et al. Pharmacokinetics of recombinant human interleukin-11 (rhIL-11) in healthy male subjects. Br J Clin Pharmacol 1997 Jun; 43: 571-8
27. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996 May 1; 87: 3615-24
28. Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997 Nov; 15: 3368-77
29. Tepler I, Elias L, Smith II JW, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996 May 1; 87: 3607-14
30. Hussein A, Fisher D, Vredenhurgh J, et al. Phase 2 trial of Neumega (Rm) rhIL-11 in patients with breast cancer after high-dose chemotherapy with bone marrow and peripheral blood stem cell support [abstract]. Blood 1996 Nov 15; 88 Suppl. 1 (Pt 1): 300a
31. Champlin RE, Mehra R, Kaye JA, et al. Recombinant human interleukin eleven (rhIl-11) following autologous BMT for breast cancer [abstract]. Blood 1994 Nov 15; 84 Suppl. 1: 395a
32. Smith IIJW, Beach K, Loewy J, et al. Integrated analysis of two placebo-controlled studies of Neumega (Rm) (rhIL-11) to prevent severe chemotherapy-induced thromhocytopenia [abstract]. 33rd Proc Am Soc Clin Oncol 1997 May 17: 111a
33. Ali-Nazir A, Davenport V, Reaman G, et al. A phase I/II trial of rhIL-11 following ifosfamide, carboplatin, and etoposide (ICE) chemotherapy in pediatric patients (pts) with solid tumors (ST) or lymphoma (L) enhancement of hematological reconstitution [abstract]. Proc Am Soc Clin Oncol 1996 Mar; 15: 274
34. Dykstra K, Rogge H, Stone A, et al. Effect of diuretic treatment on rhIL-11-induced salt and water retention [abstract]. Blood 1996 Nov 15; 88 Suppl. 1 (Pt 1): 346a
35. Champlin R, Mehra R, Kaye J, et al. Phase I study of recombinant human interleukin-11 following autologous BMT in patients with breast cancer [abstract]. Proc Am Soc Clin Oncol 1994 Mar; 13: 100
36. Teicher BA, Holden SA, Chen Y-N, et al. Interaction of recombinant human interleukin eleven with cytotoxic cancer therapies in vitro and in vivo [abstract]. Blood 1995 Nov 15; 86 Suppl. 1: 705a
37. Bammer T, Geissler D, Fenaux P, et al. Interleukin-6, interleukin-11 and leukemia inhibitory factor are candidates for in vivo stimulation of megakaryopoiesis [abstract]. Ann Oncol 1994; 5 Suppl. 5: 108
38. Hamblin T. Cytokines to reduce platelet transfusions: non-TPO cytokines. Transfus Sci 1997 Mar; 18: 121-8